Longevity & AgingOnce-Daily Pill Cuts Body Weight 11% in Major Obesity Trial
The ATTAIN-1 phase 3 trial tested orforglipron, a first-of-its-kind oral small-molecule GLP-1 receptor agonist, in 3,127 adults with obesity over 72 weeks. Unlike injectable GLP-1 drugs such as semaglutide, orforglipron is a daily pill requiring no refrigeration or injections. The highest dose (36 mg) produced an average 11.2% body weight reduction versus 2.1% with placebo. Over half of patients on the top dose lost at least 10% of body weight. Improvements were also seen in waist circumference, blood pressure, triglycerides, and cholesterol. Side effects were mainly mild-to-moderate gastrointestinal symptoms, consistent with the GLP-1 drug class. Funded by Eli Lilly, this trial positions orforglipron as a potentially accessible oral alternative to injectable obesity therapies.
